AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
The podcast episode features discussions on improving the efficacy of drug approvals in Myelodysplastic Syndromes (MDS), featuring insights from experts in the field. The speakers address the heterogeneity of MDS and the need for precision medicine approaches to better match patients with appropriate clinical trials. They highlight the importance of collaborative efforts between the National Cancer Institute and cooperative groups to develop clinical trials and find therapies for MDS patients. The session also focuses on challenging patient populations, such as those with TP53 mutations, and explores potential treatments like APR246 and its impact on higher-risk MDS. The overall emphasis is on learning from these trials to refine future treatment approaches in MDS.